Filspari (sparsentan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	:	_ MEMBER'S FIRST	NAME:	
	view (e.g., chart notes or	lab data, to support tl	y. Attach any additional documentation ne authorization request). Information	
			☐ URGENT	
MEMBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRT	H:	
STREET ADDRESS:		,		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	D NUMBER:			
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG)	: ALLERGIES:	
FOLLOWING LINK: PRIMPATIENT'S AUTHORIZE	ZATION FORM WITH TH METHERAPEUTICS.COM D REPRESENTATIVE (IF	IIS REQUEST WHICH MINOPP FAPPLICABLE):	H CAN BE FOUND AT THE	
AUTHORIZED REPRESE	NTATIVE'S PHONE NUI	MBER:		
PRESCRIBER INFORM	ATION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:	
		,		
MEDICATION OR MEDI	CAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:	
DURATION OF THERAF	Y (SPECIFIC DATES):			
Continued on next page				

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 2.1.2025 CAT009



Filspari (sparsentan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	AME:			
1. HAS THE PATIENT TRIED ANY YES (if yes, complete below)	OTHER MEDICATIONS FOR THIS	CONDITION?			
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Primary immunoglobulin A nephropathy (IgAN) ☐ Other diagnosis: ICD-10 Code(s):					
3. REQUIRED CLINICAL INFORMATION : PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Will the patient be using the drug	as a part of the clinical trial?	es 🗌 No			
Was the patient diagnosis of primary immunoglobulin A nephropathy (lgAN) confirmed via renal biopsy? (Documentation required) \square Yes \square No					
Does the patient have proteinuria of at least 1 gram per day? (Documentation required) ☐ Yes ☐ No					
Does the patient have a Urine Protein Creatinine Ratio (UPCR) of at leasr 0.8 g/g on a 24-hour urine collection? (Documentation required) \square Yes \square No					
Does the patient have an estimated eGFR of at least 30 mL/min/1.73 m2? ☐ Yes ☐ No					
Has the patient been on a maximum tolerate dose of an angiotensin converting enzyme (ACE) inhibitor or a Angiotensin II receptor blocker? (Documentation required) \square Yes \square No					
If no to the question above, does the patient have an absolute contraindication to angiotensin converting enzyme (ACE) inhibitor or a Angiotensin II receptor blocker? (Documentation required) Yes No					
Will the patient discontinue the use of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE inhibitors, ARBs), and Tekturna prior to initiating treatment with Filspari (sparsentan)? ☐ Yes ☐ No					
Does the patient have a history of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) (documentation required)? Yes No					
Will Filspari (sparsentan) be used in combination with Tarpeyo (budesonide)? ☐ Yes ☐ No					





Filspari (sparsentan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
Is Filspari (sparsentan) being prescribed by, or in consultation with, a nephrologist? Yes No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are cover required information is received.	red on all plans. This request may be denied unless all			
understand that the Health Plan, insurer, Medic	ded is true and accurate to the best of my knowledge. I cal Group or its designees may perform a routine audit and verify the accuracy of the information reported on this form.			
Prescriber Signature or Electronic I.D. Verif	fication: Date:			
information that is legally privileged. If you are disclosure, copying, distribution, or action taken	s accompanying this transmission contain confidential health not the intended recipient, you are hereby notified that any en in reliance on the contents of these documents is strictly on in error, please notify the sender immediately (via return of these documents.			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

